Weight Loss Peptides Beyond Semaglutide: What's Next?

February 15, 2026

The Current Landscape

Semaglutide and Tirzepatide have established GLP-1-based therapies as the most effective pharmaceutical approach to weight loss ever developed. But the pipeline behind them is deep, with several next-generation compounds targeting even greater efficacy, oral delivery, and additional metabolic benefits. Here is what is coming.

Retatrutide (Triple Agonist)

Developer: Eli Lilly. Mechanism: GLP-1 + GIP + Glucagon receptor triple agonist.

Retatrutide is the frontrunner among next-generation weight loss peptides. Phase 2 data showed 24.2% body weight loss at the highest dose over 48 weeks — roughly 50% more effective than Semaglutide. The glucagon component adds metabolic rate increases and liver fat reduction that other GLP-1 agonists do not provide. It also showed 86% resolution of fatty liver disease in a sub-study. Phase 3 trials are ongoing.

CagriSema (Cagrilintide + Semaglutide)

Developer: Novo Nordisk. Mechanism: Amylin analog (Cagrilintide) combined with GLP-1 agonist (Semaglutide) in a single injection.

CagriSema attacks appetite through two independent pathways. Amylin is a hormone co-secreted with insulin that signals fullness to the brain through different receptors than GLP-1. The Phase 3 REDEFINE trials showed approximately 22-25% body weight loss, putting it competitive with Tirzepatide and Retatrutide. It is Novo Nordisk's answer to Eli Lilly's dual and triple agonists.

Survodutide (GLP-1 + Glucagon)

Developer: Boehringer Ingelheim / Zealand Pharma. Mechanism: GLP-1 + Glucagon dual agonist.

Survodutide targets the same two receptors as Retatrutide minus GIP. Phase 2 data showed up to 19% weight loss over 46 weeks and impressive liver fat reduction (up to 87% reduction in liver fat content). It is being developed primarily for NAFLD/NASH in addition to obesity, positioning it as a liver-focused weight loss compound.

Orforglipron (Oral GLP-1)

Developer: Eli Lilly. Mechanism: Small molecule oral GLP-1 receptor agonist.

Orforglipron is not a peptide — it is a small molecule that activates GLP-1 receptors. This matters because small molecules are far easier to formulate as oral pills than peptides. While Rybelsus (oral Semaglutide) exists, it requires special absorption enhancers and fasting. Orforglipron can be taken as a simple daily pill without food restrictions.

Phase 2 data showed 14.7% weight loss over 36 weeks. While less than injectable Semaglutide, the convenience of a daily pill with no injection and no fasting requirement could make it the most widely adopted option. Phase 3 trials are ongoing.

Pemvidutide and Mazdutide

Pemvidutide (Altimmune): A GLP-1/Glucagon dual agonist similar to Survodutide. Phase 2 data showed up to 15.6% weight loss over 48 weeks with strong liver fat reduction. Positioned primarily for NAFLD/NASH.

Mazdutide (Innovent Biologics / Eli Lilly): A GLP-1/Glucagon dual agonist primarily being developed in China. Phase 3 data from Chinese trials showed up to 17% weight loss. It may become the first approved GLP-1/Glucagon dual agonist if it reaches approval before Survodutide and Retatrutide.

What This Means

The trend is clear: the next generation of weight loss medications will target multiple receptor systems simultaneously (GLP-1, GIP, glucagon, amylin) to achieve 20-25%+ weight loss, while also providing benefits for liver fat, cardiovascular disease, and metabolic syndrome.

Oral options like Orforglipron could dramatically expand access by eliminating the injection barrier that prevents many patients from starting treatment.

For now, Semaglutide and Tirzepatide remain the only approved and available options. Retatrutide and CagriSema are the closest to potential approval, likely in 2027-2028. Consult a healthcare provider for current treatment options.

Related Peptides

Semaglutide

The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.

Tirzepatide

Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.

Retatrutide

The first weight loss drug to target three appetite and metabolism hormones at once (GIP, GLP-1, and glucagon). In early trials, people lost up to 24% of their body weight — the highest ever recorded for any weight loss medication. The third hormone target (glucagon) helps burn more calories and reduce liver fat, going beyond what current drugs like semaglutide or tirzepatide can achieve. Still in clinical trials.

Survodutide

A weight loss injection being developed specifically for both obesity and fatty liver disease (MASH). It reduces appetite through one pathway while simultaneously telling your liver to burn its stored fat through another. This dual approach tackles the root cause (eating too much) and the downstream damage (fat build-up in the liver) at the same time. Still in clinical trials.

CagriSema

A once-weekly injection that combines two powerful appetite-suppressing drugs — cagrilintide and semaglutide — into a single shot. By targeting two different hunger pathways in the brain simultaneously, it achieves roughly 25% body weight loss in trials, making it one of the most effective weight loss treatments ever developed. Think of it as the next generation beyond Wegovy. Still awaiting FDA approval.

Cagrilintide

A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.